Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Study Shows Racial Disparities in Risk of Lupus Induced Organ Diseases
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Debra W.
Received at Testimonial Submit Form Friday, April 29, 2022 at 13:01:48
(Unedited)

Hi, my name is Debra. Thank you for your patience in explaining how EZorb works.

I've been on EZorb for two and a half years. In 2021 my bone density showed no change and even slight decline in my hip. It caught me by surprise and I was quite upset because I had been taking EZorb diligently for over a year.

I didn't want to quit because it has been helping with my arthritis pain. I called the company to find out why it hadn't yet helped with my bones. The specialist walked me through things that could go wrong and concluded that I didn't eat enough protein.

She explained to me that bones are mostly composed of protein and EZorb needs protein to create new bones. And she's right. I don't eat red meat and seldomly eat chicken or fish.

So I started eating more or less chicken or fish or eggs every day.

My recent scan results came back and sure enough my numbers have increased across the board! Big increase 7.2% in the hip and 2.3% in lumbar spine!

Thank you so much!

Letter II: From Phil L.
Received at sharesuccess @ ezorbonline.com Tue, April 12 at 04:32 PM
(Unedited)

Hi there,

I'm a runner and I run at least 5 miles a day. I've had a bone spur in my big toe for 2-3 years. It didn't bother me much at the beginning. Then it grow bigger but I was able to run through the pain. Eventually it came to a point that I couldn't deal with it any more.

My doctor wanted to have a surgery to remove the spur but I was very hesitant. I worried that I wouldn't be able to run if anything goes wrong. I read online many bad experiences of those type of surgeries.

Then I learned a peer runner from my previous cross country team used EZorb to get rid of his heel spur. I reconnected with him and he couldn't say enough about EZorb.

I purchased 6 bottles right away. Over the next 3 months, I could visibly see the spur disappearing from my eyes. The spur is still there but of much smaller size. Eventually I hope it will be gone completely. But at least it doesn't bother me no more.

All the best,

Phil L.

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

Hispanic and Asian people with systemic lupus erythematosus (SLE) are at significantly greater risk for developing renal, hematologic, and multiorgan disease than their White counterparts, US study findings indicate.

Furthermore, “renal and hematologic disease tended to occur in early SLE, with faster time to onset among Hispanic and Asian patients,” write Alfredo Aguirre (University of California, San Francisco) and co-authors in Arthritis Care & Research.

Their longitudinal California Lupus Epidemiology Study (CLUES) included 326 participants (mean age 45 years, 89% women) with SLE (mean duration 16 years). The cohort was racially and ethnically diverse, with 36% self-reporting as Asian, 30% White, 23% Hispanic, and 11% Black.

The researchers report that, by organ system, musculoskeletal (81%) and mucocutaneous (76%) manifestations were most common.

Renal disease (51%) was the most common end-organ manifestation, followed by hematologic (20%), neurologic (20%), cardiovascular (13%), and pulmonary (6%) disease, with median times to onset ranging from 0 years for hematologic manifestations to 16 years for cardiovascular disease.

Multiorgan disease was present in 29% of participants, of whom 74% had two organ systems involved, 24% had three, and 2% had four.

Adjusted analyses showed that Hispanic participants had a significantly higher risk for renal, hematologic, and multiorgan disease following SLE diagnosis than White participants, at hazard ratios (HRs) of 2.93, 2.72, and 3.28, respectively.

There was a similar pattern of elevated risk for Asian participants, with corresponding HRs of 2.92, 2.07, and 2.51.

Aguirre and team also found that time to onset of multiorgan disease, as well as renal and hematologic disease, was significantly shorter for Hispanic and Asian participants than it was for White participants.

The investigators note that there were no significant associations between race and ethnicity and neurologic or cardiovascular disease outcomes and no significant difference in outcomes between Black and White participants. However, this latter observation may be explained by the small number of Black people enrolled in the study, they say.

Aguirre et al conclude that their “study sheds light on interesting temporal trends in SLE disease trajectories” and “in particular highlights the burden of multiorgan involvement in Hispanic and Asian participants, which warrants further study to delineate the health impacts of severe, multiorgan SLE in these populations.”

Original research was published in Arthritis Care Res 2022; doi:10.1002/acr.24892.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index